AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32519555 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure with improved ejection fraction (LVEF ≤40% at baseline and improved to >40% at follow-up)
Number of subjects: 2104
Study 32519555 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent heart failure with reduced ejection fraction (persistent HFrEF, LVEF ≤40% at baseline and follow-up)
Number of subjects: 2104
Study 32519555 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent heart failure with preserved ejection fraction (persistent HFpEF, LVEF >40% at baseline and follow-up)
Number of subjects: 2104
Study 32519555 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure with declined ejection fraction (LVEF >40% at baseline and declined to ≤40% at follow-up)
Number of subjects: 2104
Study 32519555 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause mortality rates
Number of subjects: 2104
Study 32519889 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter VSD closure
Number of subjects: 60
Study 32519889 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (observation group)
Number of subjects: 60
Study 32520406 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound imaging
Number of subjects: 100
Study 32520406 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound predictive model
Number of subjects: 100
Study 32520876 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein diet (PRO, ~30% energy from protein; n = 20)
Number of subjects: 72
Study 32520876 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein diet plus exercise (PRO + EX; n = 19)
Number of subjects: 72
Study 32520876 — intervention group
Group type: COMPARATOR
Intervention: Conventional protein control diet plus exercise (CON + EX, ~18% energy from protein; n = 22)
Number of subjects: 72
Study 32521310 — intervention group
Group type: EXPERIMENTAL
Intervention: Camidanlumab tesirine at 3-92 μg/kg Q3W (n = 26) or 30 or 37.5 μg/kg QW (n = 9)
Number of subjects: 35
Study 32521310 — intervention group
Group type: EXPERIMENTAL
Intervention: Camidanlumab tesirine
Number of subjects: 35
Study 32521607 — intervention group
Group type: EXPERIMENTAL
Intervention: B cell targeted therapies
Number of subjects: 0
Study 32521607 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-mediated inflammation targeting (CANTOS study)
Number of subjects: 0
Study 32522161 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncovered self-expanding metal stent (SEMS)
Number of subjects: 113
Study 32522280 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-to-creatinine ratio (I:Cr) at 25th percentile (59 μg/g)
Number of subjects: 6971
Study 32522280 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-to-creatinine ratio (I:Cr) at 75th percentile (121 μg/g)
Number of subjects: 6971
Study 32522280 — intervention group
Group type: COMPARATOR
Intervention: Urinary iodine concentration (UIC)
Number of subjects: 6971
Study 32522280 — intervention group
Group type: COMPARATOR
Intervention: Other birth outcomes (stillbirth, preterm birth, ultrasound growth measures, congenital anomalies)
Number of subjects: 6971
Study 32522676 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrolled patients in the CURES registry
Number of subjects: 14937
Study 32522679 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34+/KDR+/CD45- cells
Number of subjects: 149
Study 32522679 — intervention group
Group type: EXPERIMENTAL
Intervention: CD133+/KDR+/CD45- cells
Number of subjects: 149
Study 32522679 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 149
Study 32522679 — intervention group
Group type: EXPERIMENTAL
Intervention: Ejection fraction
Number of subjects: 149
Study 32522743 — intervention group
Group type: EXPERIMENTAL
Intervention: EPP
Number of subjects: 3
Study 32522743 — intervention group
Group type: COMPARATOR
Intervention: NP
Number of subjects: 3
Study 32522743 — intervention group
Group type: EXPERIMENTAL
Intervention: LPP
Number of subjects: 3
Study 32522846 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE2 activity enhancement drugs
Number of subjects: 0
Study 32522846 — intervention group
Group type: EXPERIMENTAL
Intervention: RAS blockers (ACE inhibitors and angiotensin II receptor blockers)
Number of subjects: 0
Study 32523075 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced post-processing methods for predicting prostate cancer aggressiveness
Number of subjects: 0
Study 32523090 — intervention group
Group type: EXPERIMENTAL
Intervention: E7449 (600 mg, maximum-tolerated dose)
Number of subjects: 41
Study 32523090 — intervention group
Group type: EXPERIMENTAL
Intervention: E7449 (50-800 mg doses)
Number of subjects: 41
Study 32523090 — intervention group
Group type: EXPERIMENTAL
Intervention: E7449 (800 mg)
Number of subjects: 41
Study 32523090 — intervention group
Group type: EXPERIMENTAL
Intervention: E7449 (600 mg)
Number of subjects: 41
Study 32523090 — intervention group
Group type: EXPERIMENTAL
Intervention: E7449
Number of subjects: 41
Study 32523632 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel plus gemcitabine (nab-P/Gem)
Number of subjects: 102
Study 32523649 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Number of subjects: 0
Study 32523648 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin alone (Arm A)
Number of subjects: 22
Study 32523648 — intervention group
Group type: COMPARATOR
Intervention: Metformin with rapamycin (Arm B)
Number of subjects: 22
Study 32523648 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (A and B)
Number of subjects: 22
Study 32523724 — intervention group
Group type: EXPERIMENTAL
Intervention: School Health Education Program in Pakistan (SHEPP)
Number of subjects: 982
Study 32523724 — intervention group
Group type: COMPARATOR
Intervention: Routine activity (Control)
Number of subjects: 982
Study 32523972 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezlotoxumab (10 mg/kg)
Number of subjects: 1554
Study 32523972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1554
Study 32523972 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezlotoxumab
Number of subjects: 1554
Study 32524033 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept
Number of subjects: 25
Study 32524033 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes with highest retinal arteriolar oxygen saturation
Number of subjects: 25
Study 32524033 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher retinal arteriolar oxygen saturation
Number of subjects: 25
Study 32524053 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel monotherapy at 4 mg/d during the 26-week Maintenance Period
Number of subjects: 89
Study 32524053 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel monotherapy at 4 or 8 mg/d during the 26-week Maintenance Period
Number of subjects: 89
Study 32524053 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel monotherapy at 4 mg/d during Maintenance
Number of subjects: 89
Study 32524053 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel monotherapy at 4 or 8 mg/d during Maintenance
Number of subjects: 89
Study 32524257 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT) with alglucosidase alfa
Number of subjects: 396
Study 32524297 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 0
Study 32524297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32524319 — intervention group
Group type: EXPERIMENTAL
Intervention: ABBV-176 (2.7-109.35 μg/kg)
Number of subjects: 19
Study 32524319 — intervention group
Group type: EXPERIMENTAL
Intervention: ABBV-176
Number of subjects: 19
Study 32524356 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-transplantation cyclophosphamide (PT-Cy) combined with cyclosporine as GVHD prophylaxis
Number of subjects: 31
Study 32524580 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretation biases
Number of subjects: 105
Study 32524580 — intervention group
Group type: EXPERIMENTAL
Intervention: RSA suppression
Number of subjects: 105
Study 32524857 — intervention group
Group type: EXPERIMENTAL
Intervention: Sense of coherence (SOC) measured using the 13-item SOC scale (range 13-91)
Number of subjects: 4028
Study 32524857 — intervention group
Group type: EXPERIMENTAL
Intervention: Sense of coherence (SOC)
Number of subjects: 4028
Study 32524920 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 460
Study 32524920 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 460
Study 32525018 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic bedside screening for dysphagia within 3 hours postextubation
Number of subjects: 933
Study 32525018 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline neurologic disease
Number of subjects: 933
Study 32525018 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency admission
Number of subjects: 933
Study 32525018 — intervention group
Group type: EXPERIMENTAL
Intervention: Days on mechanical ventilation
Number of subjects: 933
Study 32525018 — intervention group
Group type: EXPERIMENTAL
Intervention: Days on renal replacement therapy
Number of subjects: 933
Study 32525018 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease severity (APACHE II score within first 24 hours)
Number of subjects: 933
Study 32525018 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased BMI
Number of subjects: 933
Study 32525412 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmony transcatheter pulmonary valve (TPV)
Number of subjects: 20
Study 32525412 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter valve-in-valve procedure (Melody TPV)
Number of subjects: 20
Study 32525412 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography scans
Number of subjects: 20
Study 32525844 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma transfusion
Number of subjects: 5000
Study 32525901 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic fractures (no specific intervention mentioned)
Number of subjects: 184
Study 32526533 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 10005
Study 32526533 — intervention group
Group type: EXPERIMENTAL
Intervention: DOACs
Number of subjects: 10005
Study 32526533 — intervention group
Group type: COMPARATOR
Intervention: Warfarin or DOACs
Number of subjects: 10005
Study 32526633 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal Resistive Index (RRI)
Number of subjects: 371
Study 32526633 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous Impedance Index (VII)
Number of subjects: 371
Study 32526633 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall diagnostic accuracy of RRI and VII
Number of subjects: 371
Study 32527223 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic standing sessions
Number of subjects: 12
Study 32527223 — intervention group
Group type: COMPARATOR
Intervention: Static standing sessions
Number of subjects: 12
Study 32527223 — intervention group
Group type: COMPARATOR
Intervention: Sitting
Number of subjects: 12
Study 32527223 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged 4-h standing
Number of subjects: 12
Study 32527240 — intervention group
Group type: EXPERIMENTAL
Intervention: CT ASPHINA 409 IOL
Number of subjects: 282
Study 32527396 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 2652
Study 32527643 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous anti-EGFR chimeric antigen receptor-modified T (CAR T-EGFR) cells, median dose of CAR T cells: 3.48 × 10^6 cells, administered in one to three cycles within 6 months.
Number of subjects: 16
Study 32527687 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance practitioner midwife group (DPMG)
Number of subjects: 160
Study 32527687 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance practitioner spouse/partner group (DPSG)
Number of subjects: 160
Study 32527687 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 160
Study 32527719 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 158
Study 32527868 — intervention group
Group type: EXPERIMENTAL
Intervention: Kawa-COVID-19 cohort
Number of subjects: 16
Study 32527993 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based physical activity
Number of subjects: 3096
Study 32527993 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 3096
Study 32528286 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine treatment for 12 weeks
Number of subjects: 33
Study 32528389 — intervention group
Group type: EXPERIMENTAL
Intervention: Dog-assisted therapy (DAT)
Number of subjects: 33
Study 32528460 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR T-cell products manufactured using CliniMACS Prodigy system with CD4-CD8 cell selection, lentiviral transduction, and T-cell expansion using IL-7/IL-15
Number of subjects: 28
Study 32528722 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized APD (7 × 2 L 2.27% + 5 × 2 L 0.1% over 8 h)
Number of subjects: 20
Study 32528722 — intervention group
Group type: COMPARATOR
Intervention: Standard APD (6 × 2 L 1.36% over 9 h)
Number of subjects: 20
Study 32528722 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized APD
Number of subjects: 20
Study 32528722 — intervention group
Group type: COMPARATOR
Intervention: Standard APD
Number of subjects: 20
Study 32528919 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32529175 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline for 1 year along with chemotherapy
Number of subjects: 25
Study 32529176 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-free insulin injector (NFII)
Number of subjects: 427
Study 32529176 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin pen (CIP)
Number of subjects: 427
Study 32529495 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg loading dose at weeks 0, 2, and 4, followed by 200 mg every 2 weeks up to week 48
Number of subjects: 736
Study 32529495 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) treatment
Number of subjects: 736
Study 32530434 — intervention group
Group type: EXPERIMENTAL
Intervention: Customizable colored LED lighting system
Number of subjects: 35
Study 32530436 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe City game-based intervention
Number of subjects: 1008
Study 32530436 — intervention group
Group type: COMPARATOR
Intervention: Traditional instructional materials (electronic and printed safety information)
Number of subjects: 1008
Study 32530764 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivosidenib (500 mg once per day)
Number of subjects: 66
Study 32530768 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32530906 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Volume High-Intensity Interval Training (LV-HIIT)
Number of subjects: 42
Study 32531030 — intervention group
Group type: EXPERIMENTAL
Intervention: AF ablation
Number of subjects: 230
Study 32531326 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line treatment with insulin, meglitinides or sulphonylureas
Number of subjects: 0
Study 32531326 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 0
Study 32531326 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 0
Study 32531326 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-income countries
Number of subjects: 0
Study 32531326 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of hypoglycaemia
Number of subjects: 0
Study 32531990 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional disease-modifying anti-rheumatic drug (cDMARD) therapy
Number of subjects: 0
Study 32532059 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimalarial agents (AMA)
Number of subjects: 0
Study 32532059 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32532097 — intervention group
Group type: EXPERIMENTAL
Intervention: H7N9 live attenuated influenza vaccine (LAIV) administered intranasally, two doses.
Number of subjects: 40
Study 32532097 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered intranasally, two doses.
Number of subjects: 40
Study 32532225 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-way messaging therapy
Number of subjects: 10718
Study 32532226 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin (28-day on/off regime)
Number of subjects: 17
Study 32532234 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 vaccine (four-dose series: primary three doses followed by a fourth dose approximately 18 months later)
Number of subjects: 1578
Study 32532234 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 vaccine (four-dose series)
Number of subjects: 1578
Study 32532644 — intervention group
Group type: EXPERIMENTAL
Intervention: Agitated Blood-Saline
Number of subjects: 0
Study 32532644 — intervention group
Group type: COMPARATOR
Intervention: Agitated Air-Saline
Number of subjects: 0
Study 32532797 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management Program (CDSMP)
Number of subjects: 168
Study 32532858 — intervention group
Group type: EXPERIMENTAL
Intervention: WEB treatment
Number of subjects: 61
Study 32532991 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ischemic heart preservation (NIHP)
Number of subjects: 31
Study 32532991 — intervention group
Group type: COMPARATOR
Intervention: Static cold preservation (SCS)
Number of subjects: 31
Study 32533380 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin-B hemoperfusion (PMX-HP)
Number of subjects: 28
Study 32533380 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 28
Study 32533394 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of adolescents aged 15-19 in the household
Number of subjects: 705
Study 32533394 — intervention group
Group type: COMPARATOR
Intervention: Control group (men)
Number of subjects: 705
Study 32533528 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect measurement of the respiratory exchange ratio (RER) using anaesthesia respirator; method not specified in detail.
Number of subjects: 0
Study 32534242 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg twice daily and trametinib 2 mg once daily
Number of subjects: 77
Study 32534455 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight suppression
Number of subjects: 1165
Study 32534583 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessments after 1 year and 3 years
Number of subjects: 150
Study 32534583 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain MRI
Number of subjects: 150
Study 32534583 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain cholinergic PET-imaging with fluoroethoxybenzovesamicol (FEOBV-PET)
Number of subjects: 150
Study 32534583 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain dopaminergic PET-imaging with fluorodopa (FDOPA-PET)
Number of subjects: 150
Study 32534583 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed neuropsychological assessments
Number of subjects: 150
Study 32534583 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiome composition analysis
Number of subjects: 150
Study 32534583 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal wall permeability assessment
Number of subjects: 150
Study 32534583 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 150
Study 32534583 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotyping
Number of subjects: 150
Study 32534583 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of motor and non-motor symptoms
Number of subjects: 150
Study 32534583 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle factors assessment including dietary assessment
Number of subjects: 150
Study 32534583 — intervention group
Group type: EXPERIMENTAL
Intervention: Storage of blood and feces for additional analyses
Number of subjects: 150
Study 32535123 — intervention group
Group type: EXPERIMENTAL
Intervention: Splanchnic nerve block (SNB) with ropivacaine
Number of subjects: 19
Study 32535742 — intervention group
Group type: COMPARATOR
Intervention: U100 URLi
Number of subjects: 68
Study 32535742 — intervention group
Group type: EXPERIMENTAL
Intervention: U200 URLi
Number of subjects: 68
Study 32536445 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane general anaesthesia
Number of subjects: 59
Study 32536573 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance-guided radiation therapy (MRgRT)
Number of subjects: 101
Study 32536880 — intervention group
Group type: EXPERIMENTAL
Intervention: TeleCoach™, a web-based skills training smartphone app
Number of subjects: 89
Study 32536880 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 89
Study 32536979 — intervention group
Group type: EXPERIMENTAL
Intervention: YYB101 (0.3, 1, 3, 5, 10, 20, 30 mg/kg) administered intravenously once every 4 weeks for 1 month, then once every 2 weeks until disease progression or intolerable toxicity
Number of subjects: 39
Study 32536979 — intervention group
Group type: EXPERIMENTAL
Intervention: YYB101 (20 mg/kg)
Number of subjects: 39
Study 32536979 — intervention group
Group type: EXPERIMENTAL
Intervention: YYB101
Number of subjects: 39
Study 32536979 — intervention group
Group type: EXPERIMENTAL
Intervention: YYB101 + irinotecan
Number of subjects: 39
Study 32536984 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise tapering of rhTNFR:Fc
Number of subjects: 311
Study 32536984 — intervention group
Group type: COMPARATOR
Intervention: Delayed tapering of rhTNFR:Fc
Number of subjects: 311
Study 32536984 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of rhTNFR:Fc
Number of subjects: 311
Study 32536984 — intervention group
Group type: EXPERIMENTAL
Intervention: rhTNFR:Fc 25 mg monthly
Number of subjects: 311
Study 32537166 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher LOX expression
Number of subjects: 683
Study 32537166 — intervention group
Group type: EXPERIMENTAL
Intervention: LOX expression
Number of subjects: 683
Study 32538690 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib (dosage and duration not available)
Number of subjects: 0
Study 32539108 — intervention group
Group type: COMPARATOR
Intervention: USA cohort
Number of subjects: 1114
Study 32539108 — intervention group
Group type: EXPERIMENTAL
Intervention: The Netherlands cohort
Number of subjects: 1114